Eupraxia Pharmaceuticals adds executives, shifts operations to Vancouver

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) announced changes to its executive leadership team and operating structure, according to a press release dated July 13, 2026.

Dr. Jeff Millard joined the company as Executive Vice President, Technical Operations, effective July 13, 2026. He brings nearly 25 years of experience in technical operations, chemistry, manufacturing and controls, and regulatory strategy, having previously held senior roles at Ensysce Biosciences, Microbion Corporation, and Cascadian Therapeutics.

Dr. Alex Therien, who joined Eupraxia in November 2025, will assume leadership of Research and Development as Executive Vice President. He has more than 20 years of biopharmaceutical experience, including senior roles at Generate Biomedicines, Eikon Therapeutics, and Merck.

Amanda Malone stepped down from her role as Chief Scientific and Operating Officer, effective July 10, 2026.

The company has completed a transition of its operations from Victoria, British Columbia, to Vancouver and Seattle. Key clinical, manufacturing, and commercial executive leadership positions, including the chief executive officer role, will be based in the Seattle offices.

CEO Dr. James Helliwell cited a Q4 2026 interim data release from its RESOLVE trial in Eosinophilic Esophagitis as a near-term milestone. "As we prepare for this on the back of positive data in the Phase 2a RESOLVE trial, it has been critical to ensure the Company is ready to tackle the Phase 3 development, regulatory, manufacturing and commercialization preparations," he said.

Eupraxia is a clinical-stage biotechnology company focused on locally delivered, extended-release drug products using its proprietary Diffusphere technology platform.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Roblox announces standalone apps, browser play, and creator wallet
• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial